Login / Signup

Primary Chemoradiotherapy Treatment (PCRT) for HER2+ and Triple Negative Breast Cancer Patients: A Feasible Combination.

Raquel CiervideAngel MonteroEduardo García-RicoMariola García-ArandaMercedes HerreroJessica SkaarupLeticia BenassiMaria José BarreraEstela VegaBeatriz RojasRaquel BratosAna LunaManuela ParrasMaría LópezAna DelgadoPaloma QuevedoSilvia CastillaMargarita FeyjooAna HiguerasMario PrietoAna Suarez-GauthierLina Garcia-CañamaqueNieves EscolánBeatriz ÁlvarezXin ChenRosa AlonsoMercedes LópezOvidio HernandoJeannette ValeroEmilio SánchezEva CiruelosCarmen Rubio
Published in: Cancers (2022)
Primary systemic treatment (PST) downsizes the tumor and improves pathological response. The aim of this study is to analyze the feasibility and tolerance of primary concurrent radio-chemotherapy (PCRT) in breast cancer patients. Patients with localized TN/HER2+ tumors were enrolled in this prospective study. Radiation was delivered concomitantly during the first 3 weeks of chemotherapy, and it was based on a 15 fractions scheme, 40.5 Gy/2.7 Gy per fraction to whole breast and nodal levels I-IV. Chemotherapy (CT) was based on Pertuzumab-Trastuzumab-Paclitaxel followed by anthracyclines in HER2+ and CBDCA-Paclitaxel followed by anthracyclines in TN breast cancers patients. A total of 58 patients were enrolled; 25 patients (43%) were TN and 33 patients HER2+ (57%). With a median follow-up of 24.2 months, 56 patients completed PCRT and surgery. A total of 35 patients (87.5%) achieved >90% loss of invasive carcinoma cells in the surgical specimen. The 70.8% and the 53.1% of patients with TN and HER-2+ subtype, respectively, achieved complete pathological response (pCR). This is the first study of concurrent neoadjuvant treatment in breast cancer in which three strategies were applied simultaneously: fractionation of RT (radiotherapy) in 15 sessions, adjustment of CT to tumor phenotype and local planning by PET. The pCR rates are encouraging.
Keyphrases